Literature DB >> 15021939

[Large B-cell lymphoma of the lower leg].

H Plettenberg1, S Hilton, H Stege, G Schmidt, A Kuhn, M Megahed.   

Abstract

Primary cutaneous B cell lymphomas are rare malignant lymphoproliferative disorders of the skin. The prognosis is dependent on the clinical and histologic subtype; generally, these disorders show an indolent clinical course. We describe a 80-year-old woman with a large cutaneous B cell lymphoma of the lower leg. In contrast to other variants of cutaneous B cell lymphomas, this entity is characterized by an aggressive clinical course with an unfavorable prognosis. The mean survival rate is approximately 50%. This should be taken into account in the choice of treatment.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15021939     DOI: 10.1007/s00105-004-0716-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  8 in total

1.  Large B-cell lymphoma of the leg--complete remission with perilesional interferon alpha.

Authors:  U Wollina; T Mentzel; T Graefe
Journal:  Dermatology       Date:  2001       Impact factor: 5.366

Review 2.  EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer.

Authors:  R Willemze; H Kerl; W Sterry; E Berti; L Cerroni; S Chimenti; J L Diaz-Peréz; M L Geerts; M Goos; R Knobler; E Ralfkiaer; M Santucci; N Smith; J Wechsler; W A van Vloten; C J Meijer
Journal:  Blood       Date:  1997-07-01       Impact factor: 22.113

Review 3.  Primary B-cell lymphomas of the skin.

Authors:  H Kerl; L Cerroni
Journal:  Ann Oncol       Date:  1997       Impact factor: 32.976

4.  Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study.

Authors:  F Grange; M W Bekkenk; J Wechsler; C J Meijer; L Cerroni; M Bernengo; J Bosq; G Hedelin; R Fink Puches; W A van Vloten; P Joly; M Bagot; R Willemze
Journal:  J Clin Oncol       Date:  2001-08-15       Impact factor: 44.544

5.  Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.

Authors:  L M Heinzerling; M Urbanek; J O Funk; S Peker; O Bleck; K Neuber; G Burg; P von Den Driesch; R Dummer
Journal:  Cancer       Date:  2000-10-15       Impact factor: 6.860

6.  Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.

Authors:  L Heinzerling; R Dummer; W Kempf; M H Schmid; G Burg
Journal:  Arch Dermatol       Date:  2000-03

7.  Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group.

Authors:  M H Vermeer; F A Geelen; C W van Haselen; P C van Voorst Vader; M L Geerts; W A van Vloten; R Willemze
Journal:  Arch Dermatol       Date:  1996-11

8.  Long-term efficacy, curative potential, and prognostic factors of radiotherapy in primary cutaneous B-cell lymphoma.

Authors:  Hans Theodor Eich; Dorothee Eich; Oliver Micke; Hartmut Süttzer; Claus Casper; Thomas Krieg; Rolf Peter Müller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-03-15       Impact factor: 7.038

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.